Results 201 to 210 of about 376,229 (312)
Lymphatic Abnormalities in Noonan Syndrome Extend Beyond Clinically Apparent Disease
ABSTRACT Lymphatic disease represents a well‐described manifestation of Noonan syndrome (NS), yet the full phenotypic spectrum remains incompletely characterized, especially in asymptomatic individuals. We conducted a cross‐sectional study including 10 individuals with NS (four with peripheral lymphedema and six without) and 10 age‐ and sex‐matched ...
Inger Norlyk Sheyanth +7 more
wiley +1 more source
Neutrophil-to-lymphocyte ratio as a correlative factor of severe SARS-CoV-2 infection in neonates: associations with lymphocyte subsets alterations. [PDF]
Bi G, Xiao Q, He J, Xiao S, Yang J.
europepmc +1 more source
Phenotype Expansion of Malan Syndrome: New Cases and a Review of the Literature
ABSTRACT Malan syndrome is an ultra‐rare overgrowth syndrome caused by pathogenic variants or deletions in nuclear factor one X (NFIX) located at 19p13.2. Here, we report a comprehensive literature review and phenotyping of known patients with Malan syndrome and present a novel cohort of eight patients.
Alex F. Nisbet +10 more
wiley +1 more source
Quality of neonatal intensive care in Africa: a systematic review and meta-analysis. [PDF]
Kefale AB +4 more
europepmc +1 more source
ABSTRACT Since 2015, Ann and Robert H. Lurie Children's Hospital has performed diagnostic testing for infants who screen positive for mucopolysaccharidosis type II (MPS II) on the Illinois newborn screen. Preliminary diagnostic testing includes measurement of plasma iduronate‐2‐sulfatase enzyme activity and urinary glycosaminoglycan analysis, followed ...
Carly A. Rasmussen +5 more
wiley +1 more source
Early postnatal C-reactive protein elevation during initial hospitalization in neonates with giant omphalocele undergoing delayed repair. [PDF]
Huang Z, Peng Y, Lv J, Zhong W, He Q.
europepmc +1 more source
Developmental and Phenotypic Outcomes in Mild Phenylalanine Hydroxylase Deficiency
ABSTRACT Benign hyperphenylalaninemia (bHPA) is defined as elevated phenylalanine (Phe) levels remaining ≤ 360 μmol/L (6 mg/dL) and not requiring medical intervention. Individuals with bHPA may demonstrate a rise in their Phe levels > 360 μmol/L, effectively developing a mild PKU phenotype requiring therapy to prevent neurocognitive complications. This
Aaron Williams +8 more
wiley +1 more source
Microplastics in neonates: an overlooked cost of parenteral nutrition. [PDF]
Xu D +7 more
europepmc +1 more source

